

Christopher J Black

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/214815/publications.pdf>

Version: 2024-02-01

74
papers

3,197
citations

201385

27
h-index

168136

53
g-index

74
all docs

74
docs citations

74
times ranked

1804
citing authors

#	ARTICLE	IF	CITATIONS
1	Global prevalence of irritable bowel syndrome according to Rome III or IV criteria: a systematic review and meta-analysis. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 908-917.	3.7	359
2	Prevalence of symptoms of anxiety and depression in patients with inflammatory bowel disease: a systematic review and meta-analysis. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 359-370.	3.7	256
3	Global burden of irritable bowel syndrome: trends, predictions and risk factors. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2020, 17, 473-486.	8.2	248
4	Functional gastrointestinal disorders: advances in understanding and management. <i>Lancet</i> , The, 2020, 396, 1664-1674.	6.3	216
5	British Society of Gastroenterology guidelines on the management of irritable bowel syndrome. <i>Gut</i> , 2021, 70, 1214-1240.	6.1	212
6	Systematic review with meta-analysis: efficacy of faecal microbiota transplantation for the treatment of irritable bowel syndrome. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 240-248.	1.9	144
7	Efficacy of psychological therapies for irritable bowel syndrome: systematic review and network meta-analysis. <i>Gut</i> , 2020, 69, 1441-1451.	6.1	137
8	Efficacy of pharmacological therapies in patients with IBS with diarrhoea or mixed stool pattern: systematic review and network meta-analysis. <i>Gut</i> , 2020, 69, 74-82.	6.1	122
9	Efficacy of Secretagogues in Patients With Irritable Bowel Syndrome With Constipation: Systematic Review and Network Meta-analysis. <i>Gastroenterology</i> , 2018, 155, 1753-1763.	0.6	119
10	Efficacy of a low FODMAP diet in irritable bowel syndrome: systematic review and network meta-analysis. <i>Gut</i> , 2022, 71, 1117-1126.	6.1	115
11	Chronic idiopathic constipation in adults: epidemiology, pathophysiology, diagnosis and clinical management. <i>Medical Journal of Australia</i> , 2018, 209, 86-91.	0.8	108
12	Efficacy of soluble fibre, antispasmodic drugs, and gut-brain neuromodulators in irritable bowel syndrome: a systematic review and network meta-analysis. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 117-131.	3.7	108
13	Efficacy of drugs in chronic idiopathic constipation: a systematic review and network meta-analysis. <i>The Lancet Gastroenterology and Hepatology</i> , 2019, 4, 831-844.	3.7	87
14	Epidemiological, Clinical, and Psychological Characteristics of Individuals with Self-reported Irritable Bowel Syndrome Based on the Rome IV vs Rome III Criteria. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 392-398.e2.	2.4	78
15	Efficacy of biological therapies and small molecules in moderate to severe ulcerative colitis: systematic review and network meta-analysis. <i>Gut</i> , 2022, 71, 1976-1987.	6.1	69
16	British Society of Gastroenterology guidelines on the management of functional dyspepsia. <i>Gut</i> , 2022, 71, 1697-1723.	6.1	54
17	Systematic review and network meta-analysis: efficacy of drugs for functional dyspepsia. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 8-21.	1.9	53
18	Comparison of the Rome IV criteria with the Rome III criteria for the diagnosis of irritable bowel syndrome in secondary care. <i>Gut</i> , 2021, 70, 1110-1116.	6.1	49

#	ARTICLE	IF	CITATIONS
19	Relative Efficacy of Tegaserod in a Systematic Review and Network Meta-analysis of Licensed Therapies for Irritable Bowel Syndrome With Constipation. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 1238-1239.e1.	2.4	47
20	A Novel Method to Classify and Subgroup Patients With IBS Based on Gastrointestinal Symptoms and Psychological Profiles. <i>American Journal of Gastroenterology</i> , 2021, 116, 372-381.	0.2	43
21	Efficacy of surgical or endoscopic treatment of idiopathic achalasia: a systematic review and network meta-analysis. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 30-38.	3.7	41
22	Direct healthcare costs of Rome <sc>IV</sc> or Rome <sc>III</sc>-defined irritable bowel syndrome in the United Kingdom. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 56, 110-120.	1.9	37
23	Effectiveness of management strategies for uninvestigated dyspepsia: systematic review and network meta-analysis. <i>BMJ</i> , The, 2019, 367, l6483.	3.0	36
24	Symptom Stability in Rome IV vs Rome III Irritable Bowel Syndrome. <i>American Journal of Gastroenterology</i> , 2021, 116, 362-371.	0.2	34
25	Anxiety-related factors associated with symptom severity in irritable bowel syndrome. <i>Neurogastroenterology and Motility</i> , 2020, 32, e13872.	1.6	30
26	Impact of Rome IV irritable bowel syndrome on work and activities of daily living. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 56, 844-856.	1.9	30
27	Systematic review with meta-analysis: global prevalence of uninvestigated dyspepsia according to the Rome criteria. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 762-773.	1.9	29
28	Efficacy of Oral, Topical, or Combined Oral and Topical 5-Aminosalicylates, in Ulcerative Colitis: Systematic Review and Network Meta-analysis. <i>Journal of Crohn's and Colitis</i> , 2021, 15, 1184-1196.	0.6	26
29	Best management of irritable bowel syndrome. <i>Frontline Gastroenterology</i> , 2021, 12, 303-315.	0.9	25
30	The role of multimodal treatment in Crohn's disease patients with perianal fistula: a multicentre retrospective cohort study. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 941-950.	1.9	24
31	Impact of Psychological Comorbidity on the Prognosis of Irritable Bowel Syndrome. <i>American Journal of Gastroenterology</i> , 2021, 116, 1485-1494.	0.2	24
32	Insights into the evaluation and management of dyspepsia: recent developments and new guidelines. <i>Therapeutic Advances in Gastroenterology</i> , 2018, 11, 175628481880559.	1.4	23
33	Natural History and Disease Impact of Rome IV Vs Rome III Irritable Bowel Syndrome: A Longitudinal Follow-Up Study. <i>Clinical Gastroenterology and Hepatology</i> , 2021, , .	2.4	22
34	Placebo Response Rates in Trials of Licensed Drugs for Irritable Bowel Syndrome With Constipation or Diarrhea: Meta-analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, e923-e944.	2.4	22
35	Overlap of Rome IV Irritable Bowel Syndrome and Functional Dyspepsia and Effect on Natural History: A Longitudinal Follow-Up Study. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, e89-e101.	2.4	17
36	Longitudinal follow-up of a novel classification system for irritable bowel syndrome: natural history and prognostic value. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 1126-1137.	1.9	17

#	ARTICLE	IF	CITATIONS
37	Willingness to accept risk with medication in return for cure of symptoms among patients with Rome IV irritable bowel syndrome. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 1311-1319.	1.9	16
38	Systematic review and network meta-analysis: efficacy of licensed drugs for abdominal bloating in irritable bowel syndrome with constipation. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 54, 98-108.	1.9	15
39	Rational investigations in irritable bowel syndrome. <i>Frontline Gastroenterology</i> , 2020, 11, 140-147.	0.9	14
40	Prevalence of, and predictors of, bile acid diarrhea in outpatients with chronic diarrhea: A follow-up study. <i>Neurogastroenterology and Motility</i> , 2019, 31, e13666.	1.6	11
41	Ciclosporin or Infliximab as Rescue Therapy in Acute Glucocorticosteroid-Refractory Ulcerative Colitis: Systematic Review and Network Meta-Analysis. <i>Journal of Crohn's and Colitis</i> , 2021, 15, 733-741.	0.6	10
42	Derivation and validation of a novel method to subgroup patients with functional dyspepsia: beyond upper gastrointestinal symptoms. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 253-264.	1.9	8
43	Latent class analysis does not support the existence of Rome IV functional bowel disorders as discrete entities. <i>Neurogastroenterology and Motility</i> , 2022, 34, e14391.	1.6	8
44	Peppermint Oil in Irritable Bowel Syndrome. <i>Gastroenterology</i> , 2020, 159, 395-396.	0.6	7
45	Adverse events in trials of licensed drugs for irritable bowel syndrome with constipation or diarrhea: Systematic review and meta-analysis. <i>Neurogastroenterology and Motility</i> , 2022, 34, e14279.	1.6	6
46	Assessing the Impact of Changes to the Rome IV Criteria for Clinical Practice in Irritable Bowel Syndrome. <i>Gastroenterology</i> , 2022, 162, 1752-1754.e1.	0.6	6
47	Review article: Diagnosis and investigation of irritable bowel syndrome. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 54, S33-S43.	1.9	5
48	Characteristics of, and natural history among, individuals with Rome IV functional bowel disorders. <i>Neurogastroenterology and Motility</i> , 2022, 34, e14268.	1.6	4
49	Mizagliflozin for the Treatment of Functional Constipation: Are New Drugs Better?. <i>Gastroenterology</i> , 2019, 156, 818-820.	0.6	3
50	Irritable bowel syndrome: a spotlight on future research needs. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 419-422.	3.7	3
51	Editorial: subgroups in irritable bowel syndrome—more than just diarrhoea and constipation?. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 46, 697-697.	1.9	2
52	Probiotics for Treating Irritable Bowel Syndrome: Are Bugs the Best Drugs?. <i>Gastroenterology</i> , 2018, 155, 2019-2021.	0.6	2
53	Editorial: minesapride for irritable bowel syndrome with constipation. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 713-714.	1.9	2
54	Efficacy of Eluxadoline in Irritable Bowel Syndrome With Diarrhea. <i>American Journal of Gastroenterology</i> , 2020, 115, 483-484.	0.2	2

#	ARTICLE	IF	CITATIONS
55	Use of Lactulose Breath Tests to Predict Response to Rifaximin in Irritable Bowel Syndrome With Diarrhea: The Positives and Negatives. <i>American Journal of Gastroenterology</i> , 2020, 115, 955-956.	0.2	2
56	Biochemical Tests for Bile Acid Diarrhea: Real-World Studies Required. <i>American Journal of Gastroenterology</i> , 2021, 116, 833-834.	0.2	2
57	Editorial: understanding differences in patient response to ondansetron in irritable bowel syndrome with diarrhoea—are we any closer?. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 825-826.	1.9	1
58	What is the most appropriate respiratory protection against COVID-19?. <i>BMJ Evidence-Based Medicine</i> , 2020, 26, bmjebm-2020-111441.	1.7	1
59	How effective are antibiotics for the treatment of irritable bowel syndrome?. <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 2195-2197.	0.9	1
60	Faecal incontinence is not rare in irritable bowel syndrome. <i>Frontline Gastroenterology</i> , 2020, 11, 494.2-496.	0.9	1
61	Predicting Response to Rifaximin in Irritable Bowel Syndrome with Diarrhea: Is the Answer Blowing in the Wind?. <i>Gastroenterology</i> , 2020, 158, 1508-1510.	0.6	1
62	Polyethylene glycol-based laxatives for chronic constipation — Authors' reply. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 110-111.	3.7	1
63	Prognosis of patients with Rome IV-defined versus physician-diagnosed irritable bowel syndrome: Longitudinal follow-up study. <i>Neurogastroenterology and Motility</i> , 2021, , e14282.	1.6	1
64	Efficacy of Ondansetron for Irritable Bowel Syndrome With Diarrhea. <i>American Journal of Gastroenterology</i> , 2021, 116, 428-429.	0.2	1
65	Defining the functional gastrointestinal disorders is challenging: are clinical symptoms alone sufficient?. <i>Scandinavian Journal of Gastroenterology</i> , 2018, 53, 140-140.	0.6	0
66	PWE-076—Efficacy of Pharmacological Therapies in Patients with Irritable Bowel Syndrome with Diarrhoea: Network Meta-analysis. , 2019, , .		0
67	Editorial: recognising the efficacy of licensed drug therapies for irritable bowel syndrome on bloating—a step in the right direction for targeted treatment? Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 54, 198-199.	1.9	0
68	P326—Identification of novel subgroups in irritable bowel syndrome using latent class analysis: beyond stool form. , 2021, , .		0
69	Efficacy of Senna and Magnesium Oxide for the Treatment of Chronic Idiopathic Constipation. <i>American Journal of Gastroenterology</i> , 2021, 116, 1352-1353.	0.2	0
70	Editorial: risky business. What do sufferers' perceptions of risk from interventions for IBS really mean? Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 1220-1221.	1.9	0
71	Editorial: will clusters for anxiety, depression, sleep disturbance and fatigue symptoms predict treatment outcomes in functional dyspepsia? Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 652-653.	1.9	0
72	Editorial: comorbid gastrointestinal conditions are an important consideration in IBS management—authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 1153-1154.	1.9	0

#	ARTICLE	IF	CITATIONS
73	Letter in response to Black <i>et al</i> . (2020): Authors'™ Reply. <i>Neurogastroenterology and Motility</i> , 2022, 34, e14388.	1.6	0
74	Editorial: estimating the costs of care in irritable bowel syndrome—a necessary step to enhance value-based care for a high-prevalence, low-cost condition. Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 1590-1591.	1.9	0